Stock Market 1 June 2026

XMax Stock Stays Close to Highs as 200 Million Shares Face Investors
····

XMax Stock Stays Close to Highs as 200 Million Shares Face Investors

XMax closed at $8.56, up 0.12%, staying near its 52-week high as it asked shareholders to approve discounted share sales tied to its AI expansion. The company’s proxy seeks authorization to issue up to 200 million new shares, potentially at prices up to 50% below market. XMax aims to fund AI software, hardware, and cloud infrastructure. Furniture peers saw little movement.
June 1, 2026
Cellectis Shares Dip Ahead of June Data Investors Wait For
····

Cellectis Shares Dip Ahead of June Data Investors Wait For

Cellectis ADRs fell 2.3% to $3.44 Monday amid a broader biotech downturn, with no new company disclosures. The firm plans to present Phase 1 data for its CD22-targeting CAR-T therapy at the European Hematology Association meeting on June 13. Cellectis reported $188 million in cash as of March 31, projecting funding into late 2027. Barclays initiated coverage last week with an overweight rating and a $9 target.
June 1, 2026
NHTC stock drops as investors recheck China outlook, question cash use
····

NHTC stock drops as investors recheck China outlook, question cash use

Natural Health Trends Corp. shares fell 5.1% to $2.61 Monday after the company reported a 14% drop in first-quarter revenue to $9.2 million and a net loss of $154,000. The firm cited weak consumer spending in China and cost savings from restructuring. No new updates have been posted since April 29, keeping focus on sales weakness. Cash reserves dropped to $21.2 million, with a $0.10 dividend set for May 22.
June 1, 2026
Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated
····

Lakefront Biotherapeutics Shares Drop as LKFT Gets Reevaluated

Lakefront Biotherapeutics shares fell 2.7% in Amsterdam and 1.7% in New York on Monday, extending a 15% decline this year. Bank of America disclosed a 9.3% stake as of May 20, mainly through financial instruments. The company holds €2.98 billion in cash but expects heavy spending in 2026 tied to its Gilead-Ouro partnership and cell therapy exit. Shareholders recently approved the Lakefront rebrand and new ticker LKFT.
June 1, 2026
Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision
····

Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision

Inovio Pharmaceuticals shares fell 2.7% to $1.275 after H.C. Wainwright cut its price target to $2.50, citing share dilution and focus on an FDA decision for INO-3107, expected by Oct. 30, 2026. Inovio’s share count rose to 82.3 million following a recent offering. Precigen’s rival RRP drug posted $21.6 million in Q1 sales. Inovio reported a first-quarter net loss of $19.7 million.
June 1, 2026
Airship AI Stock Moves in New York
···

Airship AI Stock Moves in New York

Airship AI shares rose 1.2% to $3.055 Monday, with trading volume near 323,000 and a market cap close to $105 million. The company last reported first-quarter revenue of $6.3 million, up 15%, and a net loss of $721,000. No new press releases or filings appeared in the past 48 hours. Airship filed a shelf registration in May allowing future securities offerings.
June 1, 2026
ICF Stock Jumps Before Shareholder Vote as Rebound Case Gets Put to Test
····

ICF Stock Jumps Before Shareholder Vote as Rebound Case Gets Put to Test

ICF International shares rose 3.3% to $71.09 on Monday ahead of its virtual annual meeting set for Tuesday. Shareholders are set to vote on a 2026 omnibus incentive plan authorizing 1,321,000 shares for awards. First-quarter revenue fell to $437.5 million from $487.6 million a year earlier, while net income dropped to $20.5 million from $26.9 million. Backlog at quarter’s end stood at $3.4 billion.
June 1, 2026
REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore
·····

REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore

REGENXBIO Inc shares slipped 0.6% to $6.97 in late morning Nasdaq trading Monday, with no new company news or filings in the past two days. The stock tracked weakness in biotech peers, including Sarepta, as investors focused on RGX-202 trial progress and the company’s cash runway. REGENXBIO last reported $150.5 million in cash at March 31, enough to fund operations into early 2027.
June 1, 2026
Trident Digital Stock Slips After Nasdaq Reprieve — What TDTH Investors Are Watching Now
····

Trident Digital Stock Slips After Nasdaq Reprieve — What TDTH Investors Are Watching Now

Trident Digital Tech Holdings’ Nasdaq-listed ADSs fell 1.9% to $2.52 Monday, reversing gains after news of regained compliance with Nasdaq’s $1 minimum bid rule and an AI partnership announcement. The company still faces a September 2026 deadline to meet Nasdaq’s $35 million market value rule. Trident reported 2025 net revenue of $160,925 and a net loss of $22.76 million. Its annual report cited “substantial doubt” about ongoing viability.
June 1, 2026
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching
····

Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching

Vistagen Therapeutics shares traded near $0.63 ahead of Monday’s Nasdaq open as investors awaited Phase 3 trial data for its lead anxiety drug, fasedienol. The company, valued at $26.6 million, expects topline results from the PALISADE-4 study this quarter. Vistagen will present at the Jefferies Healthcare Conference in New York June 2–4. The stock closed Friday at $0.630 on 654,000 shares traded.
June 1, 2026
ONEG trades flat below $1 before Nasdaq opens
····

ONEG trades flat below $1 before Nasdaq opens

OneConstruction Group Limited (ONEG) traded at $0.9292 in premarket Nasdaq action Monday, nearly flat from Friday’s $0.9300 close. The Hong Kong-based steel contractor reported a net loss of $0.1 million for the six months ended Sept. 30, 2025, down from $1.2 million profit a year earlier, as revenue slipped 3.4% to $27.8 million. Market cap stood at $14.88 million with just 732 shares traded premarket.
June 1, 2026
Sadot Up Premarket, Nasdaq Compliance Unresolved for SDOT
····

Sadot Up Premarket, Nasdaq Compliance Unresolved for SDOT

Sadot Group shares rose 4.3% to $2.85 in premarket trading Monday after a 1-for-20 reverse stock split, following a 14.4% drop Friday. The company reported zero commodity sales and a $4.9 million net loss for the first quarter. Nasdaq has flagged Sadot for failing to meet stockholders’ equity requirements. Sadot’s market cap stands near $2 million, far below major crop traders.
June 1, 2026
PENN Stock Breaks Streak; Debt Deal, Digital Bets Eyed
·····

PENN Stock Breaks Streak; Debt Deal, Digital Bets Eyed

PENN Entertainment shares fell to $18.83 in premarket trading Monday after dropping 3.14% Friday, breaking a six-day winning streak. The company extended and repriced a $962.5 million term loan B, now maturing in May 2033, lowering its interest spread. First-quarter revenue rose to $1.78 billion, with adjusted EBITDA at $265.8 million. The ESPN partnership will end Dec. 1, 2025.
June 1, 2026
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update
····

Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update

Werewolf Therapeutics shares traded near $0.45 Monday, close to a 52-week low, after entities tied to director Luke Evnin sold 141,106 shares under a preset plan, SEC filings show. The company remains under strategic review following a deal with Jazz Pharmaceuticals and repayment of K2 HealthVentures debt. Werewolf reported $46.5 million in cash as of March 31 but warned of “substantial doubt” about its ability to continue as a going concern.
June 1, 2026
1 2 3 … 126

Stock Market Today

  • Victorian government to tighten IVF clinic regulation after Monash IVF errors
    June 1, 2026, 8:32 PM EDT. The Victorian government plans stricter regulations for IVF clinics following high-profile embryo mix-ups involving Monash IVF. Health Minister Harriet Shing will gain authority to cancel clinic registrations and enforce rigorous accreditation standards under a national framework led by the Australian Commission on Safety and Quality in Health Care. The moves aim to address inconsistencies in state regulations and improve patient safety with measures like performance metrics, workforce guidelines, and safety rules for new technologies. Clinics will face a standard three-year registration, subject to review or shortening if risks are identified. Additional powers include health department inspections and equipment seizures. The changes follow a government-initiated review revealing significant shortcomings in the IVF sector.